Working with the cells of people with peanut allergies, researchers identify a "...
Health Canada has approved Chiesi Global Rare Diseases’ MYALEPTA as a treatment ...
Silence Therapeutics has announced a private placement of its 5,714,286 American...
Incyte has acquired sole worldwide rights to tafasitamab immunotherapy through a...
CB-012 is a gene-modified cell therapy commercialized by Caribou Biosciences, wi...
RT-111 could offer an alternative dosing regimen for patients with psoriasis and...
Pending a successful acquisition, Novartis will obtain pelabresib for myelofibro...
The potentially disastrous consequences of antimicrobial resistance (AMR) were h...
The Belgian women’s health company is exploring multiple asset and licensing sel...
The China NMPA has granted clearance for the investigational new drug (IND) appl...
J&J’s nipocalimab met primary endpoints in Phase III and II trials for myastheni...
“This is very significant. It’s massive.” Read about the woman suing her employe...
Novartis said late Monday it has agreed to buy German biotech MorphoSys and its ...
The bankruptcy of primary care provider Cano Health, a company once valued at $4...
A Democrat was willing to sign on to legislation that would weaken Medicare's po...
The big takeaway from CMS’ newest proposals for Medicare Advantage: the Biden ad...
